Bellicum Pharmaceuticals Competitors and Similar CompaniesClear all
Bluebird Bio's competitors and similar companies include Allogene Therapeutics and Adaptimmune.
 Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. | ||
Founding Date | Founding Date 1992 | Founding Date 2018 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Somerville, US HQ | Locations South San Francisco, US HQ | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB |
Employees | Employees 32338% decrease | Employees 2263% decrease | Employees 4007% decrease |
Valuation ($) | Valuation ($) 95.4 m | Valuation ($) 585.5 m | Valuation ($) 188.5 m |
Financial | |||
Revenue (est.) | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) |
Cost of goods | Cost of goods $89.4m (FY, 2024) | Cost of goods N/A | Cost of goods $70k (FY, 2024) |
Gross profit | Gross profit ($5.6m) (FY, 2024) | Gross profit N/A | Gross profit $178m (FY, 2024) |
Net income | Net income ($240.7m) (FY, 2024) | Net income ($190.9m) (FY, 2025) | Net income ($70.8m) (FY, 2024) |
Funding | |||
Total funding raised | Total funding raised $ 409m | Total funding raised $ 532m | Total funding raised $ 107.5m |
For sources of this data, please see the company profile
View Company Profiles
Allogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View company